Abstract
Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.
Keywords: Chemotherapy, immunotherapy, management, radiotherapy, small cell lung cancer, target therapies.
Current Drug Targets
Title:Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Volume: 18 Issue: 3
Author(s): Giuseppe Lo Russo, Marianna Macerelli, Marco Platania, Nicoletta Zilembo, Milena Vitali, Diego Signorelli, Claudia Proto, Monica Ganzinelli, Rosaria Gallucci, Francesco Agustoni, Gianpiero Fasola, Filippo de Braud and Marina Chiara Garassino
Affiliation:
Keywords: Chemotherapy, immunotherapy, management, radiotherapy, small cell lung cancer, target therapies.
Abstract: Small cell lung cancer is a highly aggressive, difficult to treat neoplasm. Among all lung tumors, small cell lung cancers account for about 20%. Patients typically include heavy smokers in 70s age group, presenting with symptoms such as intrathoracic tumors growth, distant spread or paraneoplastic syndromes at the time of diagnosis. A useful and functional classification divides small cell lung cancers into limited disease and extensive disease. Concurrent chemo-radiotherapy is the standard treatment for limited disease, with improved survival when combined with prophylactic cranial irradiation. Platinum compounds (cisplatin/carboplatin) plus etoposide remain the cornerstone for extensive disease. Nevertheless, despite high chemo- and radio-sensitivity of this cancer, nearly all patients relapse within the first two years and the prognosis is extremely poor. A deeper understanding about small cell lung cancer carcinogenesis led to develop and test a considerable number of new and targeted agents but the results are currently weak or insufficient. To date, small cell lung cancer is still a challenge for researchers. In this review, key aspects of small cell lung cancer management and controversial points of standard and new treatments will be discussed.
Export Options
About this article
Cite this article as:
Russo Lo Giuseppe, Macerelli Marianna, Platania Marco, Zilembo Nicoletta, Vitali Milena, Signorelli Diego, Proto Claudia, Ganzinelli Monica, Gallucci Rosaria, Agustoni Francesco, Fasola Gianpiero, Braud de Filippo and Garassino Chiara Marina, Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem, Current Drug Targets 2017; 18 (3) . https://dx.doi.org/10.2174/1389450117666160502152331
DOI https://dx.doi.org/10.2174/1389450117666160502152331 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Antiproliferative Effect of Novel Aminoacridine-based Compounds
Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Transcriptome and Proteome Analyses of Drug Interactions with Natural Products
Current Drug Metabolism Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics Bioactive Food Components as Dietary Intervention for Cystic Fibrosis
Current Drug Targets Perspectives on the Development of Novel Potentially Active Quinolones Against Tuberculosis and Cancer
Mini-Reviews in Medicinal Chemistry Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Cancer Immunomics in the Age of Information: Role in Diagnostics and Beyond
Current Pharmaceutical Design Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry PP-1α and PP-1γ Display Antagonism and Differential Roles in Tumorigenicity of Lung Cancer Cells
Current Molecular Medicine Modular Edge Analysis Reveals Chemotherapy-induced Brain Network Changes in Lung Cancer Patients
Current Medical Imaging